Stock Events

Stock Events

Galapagos NV 

$34.23
214
+$0.35+1.03% Today

Statistics

Day High
34.35
Day Low
33.53
52W High
37.78
52W Low
22.36
Volume
65,483
Avg. Volume
120,029
Mkt Cap
2.26B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-3.6
-2.3
-1
0.3
Expected EPS
-0.20749715817
Actual EPS
N/A

Financials

23.29%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
659.98MRevenue
153.7MNet Income

Analyst Ratings

$36.00Average Price Target
The highest estimate is 40.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLPG. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.
AMGEN
AMGN
Mkt Cap160.66B
Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.
Novartis
NVS
Mkt Cap237.61B
Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.
Merck
MRK
Mkt Cap214.76B
Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Show more...
CEO
Mr. Henry Gosebruch
Employees
704
Country
BE
ISIN
US36315X1019

Listings

MX
MX
GLPGN.MX
XETRA
DE
GXE.XETRA
BR
BE
GLPG.BR
F
DE
GXEA.F

0 Comments

Share your thoughts

FAQ

What is Galapagos NV stock price today?▼
The current price of GLPG is $34.23 USD — it has increased by +1.03% in the past 24 hours. Watch Galapagos NV stock price performance more closely on the chart.
What is Galapagos NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galapagos NV stocks are traded under the ticker GLPG.
Is Galapagos NV stock price growing?▼
GLPG stock has fallen by -0.9% compared to the previous week, the month change is a +3.82% rise, over the last year Galapagos NV has showed a +48.83% increase.
What is Galapagos NV market cap?▼
Today Galapagos NV has the market capitalization of 2.26B
When is the next Galapagos NV earnings date?▼
Galapagos NV is going to release the next earnings report on February 24, 2026.
What were Galapagos NV earnings last quarter?▼
GLPG earnings for the last quarter are -3.6 USD per share, whereas the estimation was -0.48 USD resulting in a -648.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galapagos NV revenue for the last year?▼
Galapagos NV revenue for the last year amounts to 659.98M USD.
What is Galapagos NV net income for the last year?▼
GLPG net income for the last year is 153.7M USD.
How many employees does Galapagos NV have?▼
As of February 02, 2026, the company has 704 employees.
In which sector is Galapagos NV located?▼
Galapagos NV operates in the Health Care sector.
When did Galapagos NV complete a stock split?▼
Galapagos NV has not had any recent stock splits.
Where is Galapagos NV headquartered?▼
Galapagos NV is headquartered in Mechelen, BE.